Selank (Tuftsin Analogue)

Selank and GABAergic Signalling

UKPWritten and published by UK Peptides2 min readUpdated 2 cited sources

The short answer

Reported work describes Selank influencing GABAergic signalling through changes in GABA-A receptor expression in the hippocampus, rather than by binding the receptor itself. That is mechanistically distinct from benzodiazepines, which are direct positive allosteric modulators at the GABA-A receptor.

Key facts

System
GABAergic (inhibitory)
Reported effect
Altered GABA-A receptor expression
Region cited
Hippocampus
Direct receptor binding
Not described
Benzodiazepine mechanism
Direct allosteric modulation
Model organism
Rodent

How GABA-A signalling normally works

GABA is the principal inhibitory neurotransmitter in the mammalian brain. The GABA-A receptor is a ligand-gated chloride channel: when GABA binds, chloride enters and the neuron becomes less likely to fire. Its activity can be modulated by compounds binding at sites distinct from the GABA site itself. This is what positive allosteric modulation means.

What benzodiazepines do

Benzodiazepines bind a specific allosteric site on the GABA-A receptor and increase the receptor's response to GABA. They do not open the channel themselves; they amplify the effect of GABA when it is present. Because that amplification is immediate and dose-dependent, the pharmacology is fast, powerful and associated with tolerance on sustained exposure.

Research material referenced

Selank 10mg, third-party HPLC tested

Buy Selank · £24.99

What is reported for Selank

The published description is different in kind. Selank has been reported to influence inhibitory signalling in the hippocampus through changes in GABA-A receptor expression rather than by binding the receptor. An expression-level effect operates on a slower timescale than allosteric modulation (receptor protein has to be made), and it is a distinct pharmacological category, not a variation on the same theme.

Why the distinction needs care

It is tempting to translate 'different mechanism from benzodiazepines' into a claim about comparative safety or dependence. That is not a claim the mechanism supports on its own, and it is not one that can be made about material supplied for laboratory research. What can be said accurately is narrower: the reported mechanism is expression-level rather than direct allosteric modulation, and those are different pharmacological categories.

How it sits alongside the other reported activities

GABAergic effects, enkephalinase inhibition and BDNF expression are three separately reported activities. Whether they are causally connected, or which is primary, is not established by the published work. Treating them as one unified mechanism overstates what has been shown; the literature describes several observations rather than one confirmed pathway.

Frequently asked questions

Does Selank bind the GABA receptor?

Reported work describes effects on GABA-A receptor expression rather than direct binding to the receptor.

Is that the same as how benzodiazepines work?

No. Benzodiazepines are direct positive allosteric modulators at the GABA-A receptor. An expression-level effect is a different pharmacological category operating on a slower timescale.

Are Selank's reported mechanisms connected to each other?

Not established. Enkephalinase inhibition, GABAergic effects and BDNF expression are separately reported observations rather than one confirmed pathway.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Selank (Tuftsin Analogue) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.